Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.58 |
| ▸ | MMP1 | P03956 | 8/20 | 0.58 |
| ▸ | MMP9 | P14780 | 8/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP7 | P09237 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758697 | 0.89 | ADAMTS4 (0.61) | MMP13MMP1MMP9ADAM17ADAMTS4 | |
| SCHEMBL6272434 | 0.85 | MMP13 (0.71) | MMP13MMP1MMP9ADAM17ADAMTS4 | |
| SCHEMBL6264449 | 0.79 | MMP1 (0.61) | MMP13MMP1MMP9ADAM17MMP2 | |
| SCHEMBL1655863 | 0.76 | ADAMTS4 (0.85) | MMP13MMP1MMP9ADAMTS4MMP2 | |
| SCHEMBL7981017 | 0.74 | SMN1; SMN2 (0.62) | MMP13MMP1MMP9ADAMTS4MMP2 | |
| SCHEMBL7426678 | 0.74 | MMP13 (0.44) | MMP13MMP1MMP9ADAM17ADAMTS4 | |
| SCHEMBL1770561 | 0.74 | ADAM17 (0.60) | MMP13MMP1MMP9ADAM17MMP2 | |
| SCHEMBL1770556 | 0.74 | ADAM17 (0.60) | MMP13MMP1MMP9ADAM17MMP2 | |
| SCHEMBL7354064 | 0.74 | MMP9 (0.69) | MMP13MMP1MMP9ADAM17ADAMTS4 | |
| SCHEMBL6942916 | 0.73 | ADAM17 (1.00) | MMP13MMP1MMP9ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| WO-2004093860-A1 | INHIBITORS OF SARS RELATED CORONAVIRUS PROTEINASE | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |